logo

Sofosvel

Sofosvel is the global first generic oral tablet for pan-genotypic Chronic Hepatitis C treatment. This combination (Sofosbuvir 400 mg + Valpatasvir 100 mg) drug has been approved by US FDA & European Commission for treatment of patients with all genotypic Chronic Hepatitis C virus infection. Sofosvel is used without cirrhosis or with compensated cirrhosis, and patients with advanced cirrhosis (Decompensated). Therapeutic indications:

Sofosvel is indicated for the treatment of adult patients

  • With chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infections.
  • With or without cirrhosis or with compensated cirrhosis.
  • With decompensated cirrhosis for use in combination with Ribavirin

Features

Product Name Sofosvel
Generic Name Sofosbuvir+Velpatasvir
Formulation Tablet
Available Pack Size 1x28's
Available Strength 400 mg
View Prescribing Information Visit Website